Platelet-derived growth factor-BB restores HIV Tat-mediated impairment of neurogenesis: Role of GSK-3β/β-catenin

Jie Chao, Lu Yang, Honghong Yao, Shilpa J Buch

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Our previous study demonstrated that platelet-derived growth factor-BB (PDGF-BB) increased the cell proliferation of primary rat neuronal progenitor cells (NPCs). However, whether PDGF-BB regulates neurogenesis in HIV-associated neurological disorder (HAND) remains largely unknown. In this study we demonstrated that pre-treatment of NPCs with PDGF-BB restored Tat-mediated impairment of cell proliferation via activation of p38 and JNK MAPK pathways. Moreover, treatment with PDGF-BB induced inactivation of glycogen synthase kinase-3β (GSK-3β), evidenced by its phosphorylation at Ser9, this effect was significantly inhibited by the p38 and JNK inhibitors. Level of nuclear β-catenin, the primary substrate of GSK-3β, was also concomitantly increased following PDGF-BB treatment, suggesting that PDGF-BB stimulates NPC proliferation via acting on GSK-3β to promote nuclear accumulation of β-catenin. This was further validated by gain and loss of function studies using cells transfected with either the wild type or mutant GSK-3β constructs. Together these data underpin the role of GSK-3β/β-catenin as a novel target that regulates NPC proliferation mediated by PDGF-BB with implications for therapeutic intervention for reversal of impaired neurogenesis inflicted by Tat.

Original languageEnglish (US)
Pages (from-to)259-268
Number of pages10
JournalJournal of Neuroimmune Pharmacology
Volume9
Issue number2
DOIs
StatePublished - Mar 2014

Fingerprint

Glycogen Synthase Kinase 3
Catenins
Neurogenesis
HIV
Stem Cells
Cell Proliferation
MAP Kinase Signaling System
p38 Mitogen-Activated Protein Kinases
platelet-derived growth factor BB
Nervous System Diseases
Phosphorylation

Keywords

  • Beta-catenin
  • GSK-3 beta
  • HIV Tat
  • Neuronal progenitor cell
  • PDGF-BB

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Platelet-derived growth factor-BB restores HIV Tat-mediated impairment of neurogenesis : Role of GSK-3β/β-catenin. / Chao, Jie; Yang, Lu; Yao, Honghong; Buch, Shilpa J.

In: Journal of Neuroimmune Pharmacology, Vol. 9, No. 2, 03.2014, p. 259-268.

Research output: Contribution to journalArticle

@article{6a0ea44c84344004a0a959b7d4cdf6ca,
title = "Platelet-derived growth factor-BB restores HIV Tat-mediated impairment of neurogenesis: Role of GSK-3β/β-catenin",
abstract = "Our previous study demonstrated that platelet-derived growth factor-BB (PDGF-BB) increased the cell proliferation of primary rat neuronal progenitor cells (NPCs). However, whether PDGF-BB regulates neurogenesis in HIV-associated neurological disorder (HAND) remains largely unknown. In this study we demonstrated that pre-treatment of NPCs with PDGF-BB restored Tat-mediated impairment of cell proliferation via activation of p38 and JNK MAPK pathways. Moreover, treatment with PDGF-BB induced inactivation of glycogen synthase kinase-3β (GSK-3β), evidenced by its phosphorylation at Ser9, this effect was significantly inhibited by the p38 and JNK inhibitors. Level of nuclear β-catenin, the primary substrate of GSK-3β, was also concomitantly increased following PDGF-BB treatment, suggesting that PDGF-BB stimulates NPC proliferation via acting on GSK-3β to promote nuclear accumulation of β-catenin. This was further validated by gain and loss of function studies using cells transfected with either the wild type or mutant GSK-3β constructs. Together these data underpin the role of GSK-3β/β-catenin as a novel target that regulates NPC proliferation mediated by PDGF-BB with implications for therapeutic intervention for reversal of impaired neurogenesis inflicted by Tat.",
keywords = "Beta-catenin, GSK-3 beta, HIV Tat, Neuronal progenitor cell, PDGF-BB",
author = "Jie Chao and Lu Yang and Honghong Yao and Buch, {Shilpa J}",
year = "2014",
month = "3",
doi = "10.1007/s11481-013-9509-x",
language = "English (US)",
volume = "9",
pages = "259--268",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Platelet-derived growth factor-BB restores HIV Tat-mediated impairment of neurogenesis

T2 - Role of GSK-3β/β-catenin

AU - Chao, Jie

AU - Yang, Lu

AU - Yao, Honghong

AU - Buch, Shilpa J

PY - 2014/3

Y1 - 2014/3

N2 - Our previous study demonstrated that platelet-derived growth factor-BB (PDGF-BB) increased the cell proliferation of primary rat neuronal progenitor cells (NPCs). However, whether PDGF-BB regulates neurogenesis in HIV-associated neurological disorder (HAND) remains largely unknown. In this study we demonstrated that pre-treatment of NPCs with PDGF-BB restored Tat-mediated impairment of cell proliferation via activation of p38 and JNK MAPK pathways. Moreover, treatment with PDGF-BB induced inactivation of glycogen synthase kinase-3β (GSK-3β), evidenced by its phosphorylation at Ser9, this effect was significantly inhibited by the p38 and JNK inhibitors. Level of nuclear β-catenin, the primary substrate of GSK-3β, was also concomitantly increased following PDGF-BB treatment, suggesting that PDGF-BB stimulates NPC proliferation via acting on GSK-3β to promote nuclear accumulation of β-catenin. This was further validated by gain and loss of function studies using cells transfected with either the wild type or mutant GSK-3β constructs. Together these data underpin the role of GSK-3β/β-catenin as a novel target that regulates NPC proliferation mediated by PDGF-BB with implications for therapeutic intervention for reversal of impaired neurogenesis inflicted by Tat.

AB - Our previous study demonstrated that platelet-derived growth factor-BB (PDGF-BB) increased the cell proliferation of primary rat neuronal progenitor cells (NPCs). However, whether PDGF-BB regulates neurogenesis in HIV-associated neurological disorder (HAND) remains largely unknown. In this study we demonstrated that pre-treatment of NPCs with PDGF-BB restored Tat-mediated impairment of cell proliferation via activation of p38 and JNK MAPK pathways. Moreover, treatment with PDGF-BB induced inactivation of glycogen synthase kinase-3β (GSK-3β), evidenced by its phosphorylation at Ser9, this effect was significantly inhibited by the p38 and JNK inhibitors. Level of nuclear β-catenin, the primary substrate of GSK-3β, was also concomitantly increased following PDGF-BB treatment, suggesting that PDGF-BB stimulates NPC proliferation via acting on GSK-3β to promote nuclear accumulation of β-catenin. This was further validated by gain and loss of function studies using cells transfected with either the wild type or mutant GSK-3β constructs. Together these data underpin the role of GSK-3β/β-catenin as a novel target that regulates NPC proliferation mediated by PDGF-BB with implications for therapeutic intervention for reversal of impaired neurogenesis inflicted by Tat.

KW - Beta-catenin

KW - GSK-3 beta

KW - HIV Tat

KW - Neuronal progenitor cell

KW - PDGF-BB

UR - http://www.scopus.com/inward/record.url?scp=84896542702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896542702&partnerID=8YFLogxK

U2 - 10.1007/s11481-013-9509-x

DO - 10.1007/s11481-013-9509-x

M3 - Article

C2 - 24248537

AN - SCOPUS:84896542702

VL - 9

SP - 259

EP - 268

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

IS - 2

ER -